AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00877487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
Study NCT00819845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: carvedilol vs ramipril
Study NCT00819845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: carvedilol vs ramipril
Study NCT02269033 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non Navigated Latinas
Description: A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged > 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
Study NCT03436433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide
Description: LCM 100mg twice a day.
Study NCT03436433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: LEV 1000mg twice a day.
Study NCT01411176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol
Description: 20 mL NPO-11 in a prefilled plastic syringe
Study NCT01411176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is included same additives as active comparator.
Study NCT01634620 — intervention group
Intervention type: DEVICE
Intervention: NIOX MINO® Instrument (09-1100)
Description: FeNO measurements will be performed according to the Perform FeNO Measurement guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)
Study NCT04263558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion child
Description: The MFS will include an idiographic measure of personal aims, symptom burden, displayed on a visual data dashboard to guide further intervention. The EMOTION intervention for children 9 to 12 years with symptoms of anxiety and/or depression will be used in a standard/long version (16 sessions) and a short (8 sessions) but optimized version, using a partial web-based solution with virtual reality (VR)-technology for behavioral experiments and exposure (in short and long version). Parental involvement: Parental participation in a 5-session parent group (high involvement) versus sharing information with parents via a brochure (low Parental involvement).
Study NCT01527656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
Study NCT04328129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: * Blood sample~* Nasopharyngeal swab.
Study NCT02659007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: 8 weeks of yoga, twice a week. sitting, standing, and floor postures with meditation and breath work
Study NCT01210846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib
Description: 1 x 1.5 mg capsule of tivozanib orally once daily for 21 days
Study NCT02764372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious games
Description: Participants played serious games developed for Kinect in the the EU FP7 STREP Project REHAB@HOME N. 306113
Study NCT02764372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exergames
Description: Participants played exergames existent in the Wii game console
Study NCT04927559 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT03364803 — intervention group
Intervention type: OTHER
Intervention: State-Trait Anxiety Inventory (STAI)
Description: The STAI provides data to help distinguish between anxiety and depression.
Study NCT03364803 — intervention group
Intervention type: OTHER
Intervention: State Food Craving Questionnaire-State (FCQ-S)
Description: The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
Study NCT03568708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estrogen
Description: In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
Study NCT00940914 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ioflupane 123I (DATSCAN®)
Description: One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
Study NCT00555334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: radiofrequency ablation
Study NCT00555334 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: radiofrequency ablation
Study NCT00555334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine or entecavir
Description: lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
Study NCT00511147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGIV3I Grifols 10%
Description: IGIV3I Grifols 10% 1 g/kg/day given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.
Study NCT03416335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-0509
Description: Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.
Study NCT03416335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-0509, Pembrolizumab
Description: Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
Study NCT03416335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-0509, Pembrolizumab
Description: Each patient treated will receive DSP-0509 at the Recommended Phase II Dose (RP2D) level as determined in Part B. It is given as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (400 mg IV q6w)
Study NCT04514289 — intervention group
Intervention type: DRUG
Intervention: Indocyanine green solution
Description: Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.
Study NCT02133066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bedside Ultrasound-Assisted Site Marking
Description: Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
Study NCT02133066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mindray M7 Ultrasound
Description: Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
Study NCT02133066 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Routine lumbar puncture
Description: Lumbar puncture will be performed per routine standard of care
Study NCT03238326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Once daily, oral tablets
Study NCT01037829 — intervention group
Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study
Study NCT04245748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram, a SSRI, commercially known as LexaproTM, is commonly prescribed for anxiety disorders and is FDA-approved for acute and maintenance treatment of MDD and GAD.
Study NCT04245748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine, a SNRI, commercially known as CymbaltaTM, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults.
Study NCT01149499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: 1000 mg Tablet
Study NCT01149499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: 1000 mg Tablet
Study NCT02484456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV 101 (4-Chlorokynurenine)
Description: L-4-chlorokynurenine (4-Cl-KYN) was developed as a prodrug that is rapidly converted in vivo to its active metabolite 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized N-Methyl-D-aspartate receptor (NMDAR) antagonist at the glycine site.
Study NCT02484456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo
Study NCT01091844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Voiding Trial
Description: After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.
Study NCT05743114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elemind Neuromodulation (ENMod)
Description: The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.
Study NCT02824029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02824029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02824029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00393198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (Mirena, BAY86-5028)
Description: Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.
Study NCT00393198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytotec
Description: Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit
Study NCT00393198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
Study NCT03638401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
Description: This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
Study NCT03792035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxinluo
Description: tid, po.
Study NCT03792035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: tid, po.
Study NCT03364283 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical position
Study NCT01116453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture on the acupoints of ST44 and ST43 of bilateral feet for 2 months, then followed-up for another 2months
Study NCT02898428 — intervention group
Intervention type: DEVICE
Intervention: Continuous glucose monitoring (CGM)
Study NCT03364803 — intervention group
Intervention type: OTHER
Intervention: Trait Food Craving Questionnaire-Trait (FCQ-T)
Description: Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.
Study NCT03364803 — intervention group
Intervention type: OTHER
Intervention: Visual Analogue Scale (VAS)
Description: A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption (How much do you think you can eat?), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark.
Study NCT03364803 — intervention group
Intervention type: OTHER
Intervention: Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant
Description: A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.
Study NCT04206813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil 9 2 dose regimen
Description: a 2-dose regimen of Gardasil 9 at 0 and 6 months
Study NCT04206813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil 9 3 dose regimen
Description: standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months
Study NCT04206813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil 9 rescue dose
Description: A rescue dose of Gardasil 9 will be given at 12 months
Study NCT03007030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT03007030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03695497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct anterior approach
Description: total hip arthroplasty with DAA
Study NCT03695497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Lateral Approach
Description: total hip arthroplasty with DLA
Study NCT03727555 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Intrathecal and intravenous LV gene therapy
Description: Direct IT and IV LV gene therapy to deliver high levels of LVs at 1-2×10\^9 multiplicity of infection/ml which carry normal ABCD1 gene
Study NCT01116453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care with medication and behavior therapy for 2 months, followed by acupuncture for additional 2 months
Study NCT02503839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: cyclooxygenase-2 inhibitor. Anti-inflammatory
Study NCT02503839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56:IC31
Description: Therapeutic and prophylactic TB vaccine
Study NCT02519270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGN002
Description: IGN002 is a monoclonal antibody fusion protein.
Study NCT04297839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate Anticoagulation Solution
Description: Regional citrate anticoagulation in extended hemodialysis sessions compared to the standard of care actually performed in these therapies (heparin or continuous saline infusion)
Study NCT04297839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (heparin or continuous saline)
Description: Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
Study NCT01502202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)
Study NCT01502202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
Study NCT01502202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed plusCIsplatin
Description: Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
Study NCT01502202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed plusCIsplatin
Description: Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
Study NCT02449837 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Blood samples will be collected at up to 4 time points before and during radiation. Blood will be collected at least 4 to 12 weeks post-treatment. Additional post-treatment blood draws will be performed at each subsequent follow-up visit to UNC (roughly \~1 month interval), up until 24 months after completion of radiation.
Study NCT01521221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand grip maneuver
Description: Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
Study NCT00003571 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Study NCT00003571 — intervention group
Intervention type: GENETIC
Intervention: tumor replication error analysis
Study NCT04140500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669
Description: Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)
Study NCT00837863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: ALTU-238 0.3 mg/kg daily
Study NCT00837863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: ALTU-238 0.6 mg/kg daily
Study NCT00837863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: ALTU-238 0.9 mg/kg daily
Study NCT00837863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Nutropin AQ 0.043 mg/kg daily
Study NCT02510495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 30 group
Description: A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
Study NCT02510495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 60 group
Description: A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
Study NCT02510495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 180 group
Description: A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.